Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Weight Loss Surgery: Patients Who Regain
Ames, Gretchen E. , Patel, Roshni H., Ames, Steven C. , Lynch, Scott

Mayo Clinic

Obesity and Weight Management | September 14, 2009 | Volume: 5 | Issue: 4 | Pages: 154-161

10.1089/obe.2009.0403 Get It

Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer
Cicek, Mine , Achenbach, Sara J., French, Amy J. , Blair, Hilary, Fink, Stephanie, Foster, Nathan R. , Kabat, Brian, Halling, Kevin C. , Cunningham, Julie M. , Cerhan, James R. , Jenkins, Robert B. , Boardman, Lisa A., Petersen, Gloria M. , Sargent, Daniel J. , Thibodeau, Stephen N. , Slager, Susan L. , Boardman, Lisa A., Alberts, Steven R. , Limburg, Paul J. , Sargent, Daniel J , Cerhan, James R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 11, 2009 | Volume: 18 | Issue: 9 | Pages: 2492-2500

10.1158/1055-9965.epi-09-0362 | PMID 19690179 Get It

Abstract Multiple genome-wide association studies have identified several susceptibility variants for colon cancer at 8q24. However, the functional roles of these variants have yet to be elucidated. Here, we evaluated the potential role of these markers in tumor progression and examined association with commonly observed structural abnormalities in this region, c-MYC amplification and chromosome fragility at FRA8C and FRA8D. We first replicated the previously reported association by testing 1,178 cases and 1,009 clinic-based controls with eight markers localized to three specific regions at 8q24. We observed significant associations with colon cancer risk with markers rs13254738 (ordinal odds ratio, 0.82; 95% confidence interval, 0.072-0.94; Ptrend = 0.0037) and rs6983267 (ordinal odds ratio, 1.17; 95% confidence interval, 1.03-1.32, Ptrend = 0.013). Survival analysis was done using a separate set of 460 cases to evaluate the clinical significance of these markers. Overall, univariate analysis did not detect survival differences for any of the markers. We also tested a subset of the 460 cases (n = 380) for structural abnormalities at or near the c-MYC locus using fluorescence in situ hybridization analysis. Furthermore, we evaluated a small number of cases homozygous for the rs6983267 alleles to test for differences in fragile site induction. None of the 8q markers correlated with amplification at the c-MYC locus as detected by fluorescence in situ hybridization, and no clear pattern of breakage was observed at the FRA8C and FRA8D sites. In this study, we confirm the association for several single nucleotide polymorphisms at 8q24 in colon cancer but have not detected any structural role relating to c-MYC amplification or chromosomal fragility. Finally, these risk alleles do not seem to be associated with survival. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2492–500)
Aspirin for the Primary Prevention of Cardiovascular Events
Calvin, Andrew D. , Aggarwal, Niti R., Murad, M. Hassan , Shi, Qian , Elamin, Mohamed B., Geske, Jeffrey B. , Fernández-Balsells, Mercè , Lampropulos, Julianna F., Erwin, Patricia J., Smith, Steven A., Montori, Víctor M. , Albuquerque, Felipe N. , Murad, M Hassan , Montori, Victor M , Shi, Qian , Geske, Jeffrey B , Calvin, Andrew D

Mayo Clinic

Diabetes Care | September 9, 2009 | Volume: 32 | Issue: 12 | Pages: 2300-2306

10.2337/dc09-1297 | PMID 19741185 Get It

OBJECTIVE The negative results of two randomized controlled trials (RCTs) have challenged current guideline recommendations for using aspirin for primary prevention of cardiovascular events among patients with diabetes. We therefore sought to determine if the effect of aspirin for primary prevention of cardiovascular events and mortality differs between patients with and without diabetes. RESEARCH DESIGN AND METHODS We conducted a systematic search of MEDLINE, EMBASE, Cochrane Library, Web of Science, and Scopus since their inceptions until November 2008 for RCTs of aspirin for primary prevention of cardiovascular events. Blinded pairs of reviewers evaluated studies and extracted data. Random-effects meta-analysis and Bayesian logistic regression were used to estimate the ratios of relative risks (RRs) of outcomes of interest among patients with and without diabetes. A 95% CI that crosses 1.00 indicates that the effect of aspirin does not differ between patients with and without diabetes. RESULTS Nine RCTs with moderate to high methodological quality contributed data to the analyses. The ratios of RRs comparing the benefit of aspirin among patients with diabetes compared with patients without diabetes for mortality, myocardial infarction, and ischemic stroke were 1.12 (95% CI 0.92–1.35), 1.19 (0.82–1.17), and 0.70 (0.25–1.97), respectively. CONCLUSIONS Whereas estimates of benefit among patients with diabetes remain imprecise, our analysis suggests that the relative benefit of aspirin is similar in patients with and without diabetes.
A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu
Peethambaram, Prema P. , Melisko, Michelle , Rinn, Kristine , Provost, Nicole , Jones, Lori , Sims, Robert B., Lin, Lisa R. C., Frohlich, Mark W., Park, John W., Alberts, Steven R.

Mayo Clinic

Clinical Cancer Research | September 2, 2009 | Volume: 15 | Issue: 18 | Pages: 5937-5944

10.1158/1078-0432.ccr-08-3282 | PMID 19723649 Get It

AbstractPurpose: This study aimed to evaluate the safety of, immune response induced by, and efficacy of treatment with lapuleucel-T (APC8024) in patients with HER-2/neu–expressing tumors. Lapuleucel-T is an investigational active immunotherapy product consisting of autologous peripheral blood mononuclear cells, including antigen presenting cells, which are cultured ex vivo with BA7072, a recombinant fusion antigen consisting of portions of the intracellular and extracellular regions of HER-2/neu linked to granulocyte-macrophage colony-stimulating factor.Experimental Design: Patients with metastatic breast, ovarian, or colorectal cancer whose tumors expressed HER-2 were eligible. Patients underwent leukapheresis in week 0 and received lapuleucel-T infusions in weeks 0, 2, and 4. Patients who achieved a partial response or had stable disease through week 48 were eligible for re-treatment using the same protocol and dose as their initial treatment.Results: Eighteen patients were enrolled and treated. Patients showed an immune response to the immunizing antigen (BA7072) at week 8 compared with week 0 as measured by T lymphocyte proliferation and IFN-γ enzyme-linked immunospot assay. Therapy was well tolerated. The majority (94.7%) of adverse events associated with treatment were grade 1 or 2. Two patients experienced stable disease lasting >48 weeks.Conclusions: Autologous active cellular immunotherapy with lapuleucel-T stimulated an immune response specific to the immunizing antigen and seemed to be well tolerated. Further clinical studies to assess the clinical benefit for patients with HER/2-neu–expressing breast, ovarian, and colorectal cancer are warranted. (Clin Cancer Res 2009;15(18):5937–44)
A Case Series of Laparoscopic Components Separation and Rectus Medialization with Laparoscopic Ventral Hernia Repair
Malik, Kashif, Bowers, Steven P. , Smith, C. Daniel, Asbun, Horacio J. , Preissler, Susanne

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | August 20, 2009 | Volume: 19 | Issue: 5 | Pages: 607-610

10.1089/lap.2009.0155 | PMID 19694565 Get It

Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells
Wada, David A., Ziesmer, Steven C., Elsawa, Sherine F. , Comfere, Nneka I. , Dietz, Allan B. , Novak, Anne J. , Feldman, Andrew L. , Pittelkow, Mark R. , Ansell, Stephen M. , Wilcox, Ryan A. , Witzig, Thomas E. , Feldman, Andrew L , Elsawa, Sherine F , Dietz, Allan B

Mayo Clinic

Blood | August 12, 2009 | Volume: 114 | Issue: 14 | Pages: 2936-2944

10.1182/blood-2009-05-220111 | PMID 19671921 Get It

A variety of nonmalignant cells present in the tumor microenvironment promotes tumorigenesis by stimulating tumor cell growth and metastasis or suppressing host immunity. The role of such stromal cells in T-cell lymphoproliferative disorders is incompletely understood. Monocyte-derived cells (MDCs), including professional antigen-presenting cells such as dendritic cells (DCs), play a central role in T-cell biology. Here, we provide evidence that monocytes promote the survival of malignant T cells and demonstrate that MDCs are abundant within the tumor microenvironment of T cell–derived lymphomas. Malignant T cells were observed to remain viable during in vitro culture with autologous monocytes, but cell death was significantly increased after monocyte depletion. Furthermore, monocytes prevent the induction of cell death in T-cell lymphoma lines in response to either serum starvation or doxorubicin, and promote the engraftment of these cells in nonobese diabetic/severe combined immunodeficient mice. Monocytes are actively recruited to the tumor microenvironment by CCL5 (RANTES), where their differentiation into mature DCs is impaired by tumor-derived interleukin-10. Collectively, the data presented demonstrate a previously undescribed role for monocytes in T-cell lymphoproliferative disorders.
Should Clinicians Deliver Decision Aids? Further Exploration of the Statin Choice Randomized Trial Results
Jones, Lesley A., Weymiller, Audrey, Shah, Nilay D. , Bryant, Sandra C. , Christianson, Teresa J., Gafni, Amiram , Smith, Steven A., Montori, Víctor M. , Guyatt, Gordon , Montori, Victor M

Mayo Clinic

Medical Decision Making | July 15, 2009 | Volume: 29 | Issue: 4 | Pages: 468-474

10.1177/0272989x09333120 | PMID 19605885 Get It

Background. Statin Choice is a decision aid about taking statins. The optimal mode of delivering Statin Choice (or any other decision aid) in clinical practice is unknown. Methods. To investigate the effect of mode of delivery on decision aid efficacy, the authors further explored the results of a concealed 2 × 2 factorial clustered randomized trial enrolling 21 endocrinologists and 98 diabetes patients and randomizing them to 1) receive either the decision aid or pamphlet about cholesterol, and 2) have these delivered either during the office visit (by the clinician) or before the visit (by a researcher). We estimated between-group differences and their 95% confidence intervals (CI) for acceptability of information delivery (1—7), knowledge about statins and coronary risk (0—9), and decisional conflict about statin use (0—100) assessed immediately after the visit. Follow-up was 99%. Results. The relative efficacy of the decision aid v. pamphlet interacted with the mode of delivery. Compared with the pamphlet, patients whose clinicians delivered the decision aid during the office visit showed significant improvements in knowledge (difference of 1.6 of 9 questions, CI 0.3, 2.8) and nonsignificant trends toward finding the decision aid more acceptable (odds ratio 3.1, CI 0.9, 11.2) and having less decisional conflict (difference of 7 of 100 points, CI - 4, 18) than when a researcher delivered the decision aid just before the office visit. Conclusions. Delivery of decision aids by clinicians during the visit improves knowledge and shows a trend toward better acceptability and less decisional conflict.
The effect of tissue culture on suture holding strength and degradation in canine tendon
Omae, Hiromichi, Zhao, Cathy , Zobitz, M. E., Moran, Steven L. , Amadio, Peter C. , Sun, Yu Long

Mayo Clinic

Journal of Hand Surgery (European Volume) | July 8, 2009 | Volume: 34 | Issue: 5 | Pages: 643-650

10.1177/1753193409104564 | PMID 19587082 Get It

The purpose of this study was to assess tendon metabolism and suture pull-out strength after simple tendon suture in a tissue culture model. One hundred and twelve flexor digitorum profundus tendons from 28 dogs were cultured for 7, 14, or 21 days with or without a static tensile load. In both groups increased levels of matrix metalloproteinase (MMP) mRNA was noted. Suture pull-out strength did not decrease during tissue culture. While the presence of a static load had no effect on the pull-out strength, it did affect MMP mRNA expression. This tissue culture model could be useful in studying the effect of factors on the tendon-suture interface.
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
Poplin, Elizabeth, Rothenberg, Mace L., Höchster, Howard S. , Mitchell, Edith P. , O’Dwyer, Peter J. , Haller, Daniel G. , Catalano, Paul J. , Cella, David , Benson, Al B. , Feng, Yang , Berlin, Jordan D. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | July 7, 2009 | Volume: 27 | Issue: 23 | Pages: 3778-3785

10.1200/jco.2008.20.9007 | PMID 19581537 Get It

PurposeSingle-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clinical trials. E6201 was designed to compare overall survival (OS) of standard weekly GEM 1,000 mg/m2/30 minutes versus GEM FDR 1,500 mg/m2/150 minutes or GEM 1,000 mg/m2/100 minutes/day 1 plus oxaliplatin 100 mg/m2/day 2 every 14 days (GEMOX).MethodsThis trial included patients with metastatic or locally advanced pancreatic cancer, normal organ function, and performance status of 0 to 2. The study was designed to detect a 33% difference in median survival (hazard ratio [HR] ≤ 0.75 for either of the experimental arms) with 81% power while maintaining a significance level of 2.5% in a two-sided test for each of the two primary comparisons.ResultsEight hundred thirty-two patients were enrolled. The median survival and 1-year survival were 4.9 months (95% CI, 4.5 to 5.6) and 16% for GEM, 6.2 months (95% CI, 5.4 to 6.9), and 21% for GEM FDR (HR, 0.83; stratified log-rank P = .04), and 5.7 months (95% CI, 4.9 to 6.5) and 21% for GEMOX (HR, 0.88; stratified log-rank P = .22). Neither of these differences met the prespecified criteria for significance. Survival was 9.2 months for patients with locally advanced disease, and 5.4 months for those with metastatic disease. Grade 3/4 neutropenia and thrombocytopenia were greatest with GEM FDR. GEMOX caused higher rates of nausea, vomiting, and neuropathy.ConclusionNeither GEM FDR nor GEMOX resulted in substantially improved survival or symptom benefit over standard GEM in patients with advanced pancreatic cancer.
Building a Protocol Expressway: The Case of Mayo Clinic Cancer Center
McJoynt, Terre A., Hirzallah, Muhanad A., Satele, Daniel , Pitzen, Jason H., Rajkumar, S. Vincent , Alberts, Steven R. , Rajkumar, S Vincent

Mayo Clinic

Journal of Clinical Oncology | June 30, 2009 | Volume: 27 | Issue: 23 | Pages: 3855-3860

10.1200/jco.2008.21.4338 | PMID 19564529 Get It

Purpose Inconsistencies and errors resulting from nonstandard processes, together with redundancies, rework, and excess workload, lead to extended time frames for clinical trial protocol development. This results in dissatisfaction among sponsors, investigators, and staff and restricts the availability of novel treatment options for patients. Methods A team of experts from Mayo Clinic formed, including Protocol Development Unit staff and management from the three Mayo Clinic campuses (Florida, Minnesota, and Arizona), a systems and procedures analyst, a quality office analyst, and two physician members to address the identified deficiencies. The current-state process was intensively reviewed, and improvement steps were taken to accelerate the development and approval of cancer-related clinical trials. The primary goal was to decrease the time from receipt of a new protocol through submission to an approving authority, such as the National Cancer Institute or institutional review board. Results Using the Define, Measure, Analyze, Improve, Control (DMAIC) framework infused with Lean waste-reduction methodologies, areas were identified for improvement, including enhancing first-time quality and processing new studies on a first-in/first-out basis. The project was successful in improving the mean turnaround time for internally authored protocols (P < .001) from 25.00 weeks (n = 41; range, 3.43 to 94.14 weeks) to 10.15 weeks (n = 14; range, 4.00 to 22.14 weeks). The mean turnaround time for externally authored protocols was improved (P < .001) from 20.61 weeks (n = 85; range, 3.29 to 108.57 weeks) to 7.79 weeks (n = 50; range, 2.00 to 20.86 weeks). Conclusion DMAIC framework combined with Lean methodologies is an effective tool to structure the definition, planning, analysis, and implementation of significant process changes.